Injectable platelet-rich fibrin (i-PRF), an autologous fibrin matrix, can be used as a vehicle to deliver drugs like Ciprofloxacin locally to periodontal sites. This assessed the effectiveness of Ciprofloxacin-loaded i-PRF (Cip-i-PRF) as an adjunct to scaling and root planing (SRP) in patients (age group of 30‒60 years) diagnosed with Stage II Grade B periodontitis.
Injectable platelet-rich fibrin is a promising local drug delivery vehicle for Ciprofloxacin, enhancing clinical outcomes in periodontal therapy when combined with scaling and root planing.
Injectable platelet-rich fibrin (i-PRF), an autologous fibrin matrix, can be used as a vehicle to deliver drugs like Ciprofloxacin locally to periodontal sites. This assessed the effectiveness of Ciprofloxacin-loaded i-PRF (Cip-i-PRF) as an adjunct to scaling and root planing (SRP) in patients (age group of 30‒60 years) diagnosed with Stage II Grade B periodontitis.
In this randomized controlled parallel design trial, 79 periodontal pocket sites were randomized into three groups:
Clinical parameters (probing depth, clinical attachment level, gingival index, plaque index) and microbial levels of Aggregatibacter actinomycetemcomitans were assessed at baseline, 6 weeks, and 12 weeks.
All treatment groups showed significant improvements in clinical and microbial outcomes. Group 1 exhibited the greatest reduction in probing depth and gingival index, along with the highest clinical attachment level gain and a significant reduction in A. actinomycetemcomitans levels at 12 weeks. Group 2 showed moderate improvements, while Group 3 had the least favorable outcomes.
Thus, i-PRF can be considered a potential local drug delivery vehicle for Ciprofloxacin in non-surgical periodontal pocket therapy. It offered enhanced clinical and microbial improvements when paired with SRP.
Journal of Advanced Periodontology & Implant Dentistry
Efficacy of injectable platelet-rich fibrin (i-PRF) as a novel vehicle for local drug delivery in non-surgical periodontal pocket therapy: A randomized controlled clinical trial
Murugan Thamaraiselvan et al.
Comments (0)